Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

• Main Authors: Barrios, C.H., Liu, M.-C., Lee, S.C., Vanlemmens, L., Ferrero, J.-M., Tabei, T., Pivot, X., Iwata, H., Aogi, K., Lugo-Quintana, R., Harbeck, N., Brickman, M.J., Zhang, K., Kern, K.A., Martin, M.
• 其他作者: CANCER SCIENCE INSTITUTE OF SINGAPORE
• 格式: Article
• 出版: 2014
• 主題: Advanced breast cancer; Capecitabine; Sunitinib malate; Tyrosine kinase inhibitor
• 在線閱讀: http://scholarbank.nus.edu.sg/handle/10635/110766

10.1007/s10549-010-0788-0